financetom
Business
financetom
/
Business
/
Colgate-Palmolive Q2 Non-GAAP Earnings, Net Sales Rise; 2024 Non-GAAP EPS Guidance Raised
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Colgate-Palmolive Q2 Non-GAAP Earnings, Net Sales Rise; 2024 Non-GAAP EPS Guidance Raised
Jul 26, 2024 4:52 AM

07:26 AM EDT, 07/26/2024 (MT Newswires) -- Colgate-Palmolive ( CL ) reported Q2 non-GAAP earnings Friday of $0.91 per diluted share, up from $0.77 a year earlier.

Analysts polled by Capital IQ expected $0.87.

Net sales for the quarter ended June 30 were $5.06 billion, up from $4.82 billion a year earlier.

Analysts polled by Capital IQ expected $5.0 billion.

For full year 2024, the company said it now expects non-GAAP EPS growth of 8% to 11%, raising its previous outlook of middle- to high-single-digit growth. Analysts surveyed by Capital IQ expect $3.53 normalized EPS.

Net sales are still expected to grow 2% to 5%. Analysts surveyed by Capital IQ expect $20.18 billion revenue.

Price: 97.92, Change: +1.43, Percent Change: +1.48

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Alnylam Pharmaceuticals Insider Sold Shares Worth $3,163,346, According to a Recent SEC Filing
Alnylam Pharmaceuticals Insider Sold Shares Worth $3,163,346, According to a Recent SEC Filing
Aug 20, 2025
05:34 PM EDT, 08/19/2025 (MT Newswires) -- Yvonne Greenstreet, Director, Chief Executive Officer, on August 15, 2025, sold 6,979 shares in Alnylam Pharmaceuticals ( ALNY ) for $3,163,346. Following the Form 4 filing with the SEC, Greenstreet has control over a total of 56,628 common shares of the company, with 56,221 shares held directly and 407 controlled indirectly. SEC Filing:...
Alnylam Pharmaceuticals Insider Sold Shares Worth $1,030,727, According to a Recent SEC Filing
Alnylam Pharmaceuticals Insider Sold Shares Worth $1,030,727, According to a Recent SEC Filing
Aug 20, 2025
05:34 PM EDT, 08/19/2025 (MT Newswires) -- Jeffrey V. Poulton, Executive Vice President, Chief Financial Officer, on August 15, 2025, sold 2,274 shares in Alnylam Pharmaceuticals ( ALNY ) for $1,030,727. Following the Form 4 filing with the SEC, Poulton has control over a total of 50,178 common shares of the company, with 50,121 shares held directly and 57 controlled...
Legalzoom.com Insider Sold Shares Worth $272,166, According to a Recent SEC Filing
Legalzoom.com Insider Sold Shares Worth $272,166, According to a Recent SEC Filing
Aug 20, 2025
05:37 PM EDT, 08/19/2025 (MT Newswires) -- Nicole Miller, Chief Legal Officer, on August 15, 2025, sold 25,154 shares in Legalzoom.com ( LZ ) for $272,166. Following the Form 4 filing with the SEC, Miller has control over a total of 960,032 common shares of the company, with 960,032 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1286139/000128613925000093/xslF345X05/wk-form4_1755639276.xml ...
Alnylam Pharmaceuticals Insider Sold Shares Worth $632,759, According to a Recent SEC Filing
Alnylam Pharmaceuticals Insider Sold Shares Worth $632,759, According to a Recent SEC Filing
Aug 20, 2025
05:36 PM EDT, 08/19/2025 (MT Newswires) -- Kevin Joseph Fitzgerald, Chief Scientific Officer, Executive Vice President, and Head of Research, on August 15, 2025, sold 1,396 shares in Alnylam Pharmaceuticals ( ALNY ) for $632,759. Following the Form 4 filing with the SEC, Fitzgerald has control over a total of 23,256 common shares of the company, with 22,719 shares held...
Copyright 2023-2026 - www.financetom.com All Rights Reserved